Reviewer 3

With interest I reviewed the manuscript submitted by Loiseau et al. They aimed to develop a new generation of titanate nanotubes (TiONts) to enhance radiotherapy in prostate cancer. The surface of TiONts was coated with a siloxane and coupled with DTDTPA-modified gold nanoparticles and a heterobifunctional polymer to improve suspension stability. Docetaxel was coupled as a therapeutic agent. The in vitro studies performed could show that this TiONts have a distinct cytotoxic activity on human PC-3 prostate cancer cells. In PC-3 xenografted tumors on mice, the TiONts prepared as mentioned above were retained within the tumor after intratumoral injection allowing to delay tumor growth after irradiation. Accordingly, this work provides an important basis for further cancer research.

In general, the manuscript is concise, very well written and the methods are sound.

However, some minor issues have to be considered:

- The abbreviations used must be introduced consequently from the beginning or already in the introduction section (e.g., STEM, XPS, etc.)

  Answer: We thank the reviewer for his/her remark. We apologize for this omission: from now on, abbreviations have been defined at their first occurrence in the text.

- As suggested by the author guidelines of Cancers, the work should be rewritten. The results and the discussion should be separated from each other. I.e., the discussion should be conducted separately in a discussion section.

  Answer: Thank you for this remark. The results and discussion parts have been separated.

Finally, the authors would like to thank the reviewer for his/her valuable questions and comments definitively bringing our manuscript to a finer level of understanding and better emphasis of our results.